Persistent low complement levels and increased interferon gene expression are predictive for disease progression in patients with incomplete systemic lupus erythematosus

Joint Bone Spine. 2022 Oct;89(5):105381. doi: 10.1016/j.jbspin.2022.105381. Epub 2022 Apr 29.

Authors

Wietske M Lambers¹, Johanna Westra², Suzanne Arends², Berber Doornbos-van der Meer², Barbara Horvath³, Hendrika Bootsma², Karina de Leeuw²

Affiliations

¹ Departments of Rheumatology & Clinical Immunology, University Medical Centre Groningen, University of Groningen, Groningen, Netherlands. Electronic address: w.m.lambers@umcg.nl.
² Departments of Rheumatology & Clinical Immunology, University Medical Centre Groningen, University of Groningen, Groningen, Netherlands.
³ Departments of Dermatology, University Medical Centre Groningen, University of Groningen, Groningen, Netherlands.

PMID: 35500799
DOI: 10.1016/j.jbspin.2022.105381

No abstract available

Keywords: Biomarker; Complement; Primary Sjögren's disease; Systemic lupus erythematosus; interferon.

Publication types

Letter
Research Support, Non-U.S. Gov't

MeSH terms

Antibodies, Antinuclear
Antiviral Agents
Disease Progression
Gene Expression
Humans
Interferons
Lupus Erythematosus, Systemic* / diagnosis
Lupus Erythematosus, Systemic* / genetics
Sjogren's Syndrome*

Substances

Antibodies, Antinuclear
Antiviral Agents
Interferons